NEW YORK (GenomeWeb) – Molecular diagnostics firm Cancer Genetics today announced that it has signed definitive agreements to sell 2,750,000 shares of common stock to institutional investors for roughly $5.5 million in gross proceeds.

For each share purchased, the investors will also receive an unregistered warrant to buy one-half of a share of common stock at an exercise price of $2.25 a share, CGI said. The warrants are exercisable six months from the date of issuance and expire five years after their initial exercise date.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.